In a small Indian town, an unusual new treatment called “tazim” has given doctors a chance to treat cancer with just a pair, a treatment that has been shown to be 100 percent effective and completely safe.
The first-of-its-kind treatment was introduced last year by Dr. Sharmila Shamsi, a clinical psychologist and professor of medicine at the Indian Institute of Medical Sciences.
She said the treatment is very similar to an existing treatment called chemo for breast cancer, but it has also been shown in multiple studies to be as effective as radiation therapy for leukemia and prostate cancer.
Shamsi said doctors are using Tazim as a treatment for two reasons.
First, it’s cheap and effective.
She explained that a patient could get a prescription from their doctors, have it delivered to their house, and have it done within two to three weeks.
The second reason for Tazims success is the fact that it’s inexpensive.
A single dose can cost less than $100, compared to more than $300 for a treatment using chemo or radiation.
The Tazimal is a device that looks like a small bag of pills.
Doctors insert a syringe into a patient’s arm and inject it with Tazima, which is a liquid version of the medicine known as a capsule.
They then insert the capsule into the patient’s tummy, where the capsule attaches to the capsule inside the Tazime.
The capsule is then attached to a capsule dispenser that takes care of all the medical details and safety measures.
The doctor can also monitor the progress of the Tazaim therapy in real time.
A new study conducted by the Indian National Institute of Cancer Research (INICR) found that when Tazimes were given to healthy volunteers, they produced similar levels of the chemo drug called chemokine-21, a chemotherapeutic protein that is a precursor of chemo drugs.
When given to patients with cancer, chemokines have been shown not only to reduce the disease’s spread but also to be effective at halting the progression of cancer.
“We showed that Tazimo significantly slowed the spread of advanced cancer in the lungs of the volunteers and in the liver of the healthy volunteers.
The volunteers showed improved lung function and were able to maintain a normal life expectancy in five years after their Tazimi treatment,” said INICR researcher Dr. Sudhir Kumar, in a statement.
In addition, Taziman is also a treatment in which the body’s immune system is stimulated to fight cancer.
This is when Tazaime stimulates the immune system to attack cancer cells, thereby suppressing their ability to spread.
In addition, a study by INICL found that Tazaimes effectiveness in suppressing the spread and progression of breast cancer was comparable to that of a combination chemotherapy treatment.
The results of the INIC study, which was published online in the journal Science Translational Medicine, indicate that Tzim treatment can be administered in the same way as chemotherapy or radiation, but also at a much lower cost.
In the future, the researchers are looking at whether Tzims effectiveness will be compared with other cancer treatments that are less expensive.
According to Dr. Darshan Bhatnagar, who studies the immune response in cancer at the Institute of Science and Technology, in the future Tazis effectiveness could be compared to the immune systems in the skin.
Bhatnar said that Tzaim could be useful in preventing skin cancers from spreading, which could make it possible for cancer patients to stay healthy.
“Tazim could potentially also be used to treat autoimmune diseases like type 1 diabetes, type 2 diabetes, and other autoimmune diseases, which are associated with the development of metastatic tumors,” he added.
“With this treatment, the immune cells in the body are stimulated to produce antibodies and suppress the immune function of the cancer cells,” said Bhatna.
“These antibodies will then activate the immune process of the body to stop the spread.
This will also allow the patient to live for a longer time.”
Source: INIC R, Bhatnanagar D, Kumar S. (2015) Tazimumab reduces cancer spread in mice.
Science Trans Lational Medicine.